Low levels of testosterone are associated with an increased risk of mortality from coronary heart disease (CHD) in postmenopausal women, reported Gail A. Laughlin, PhD.
Low levels of testosterone are associated with an increased risk of mortality from coronary heart disease (CHD) in postmenopausal women, reported Gail A. Laughlin, PhD.
Women's favorable cardiovascular risk compared with men is usually explained by endogenous estrogen levels. However, few studies have evaluated the role of naturally circulating testosterone in older women. Hyperandrogenemia in young women with polycystic ovary syndrome is associated with adverse cardiovascular risk factors, carotid atherosclerosis, and impaired vascular function, Dr. Laughlin said.
Using enrollees from the Rancho Bernardo Study, an ongoing population-based study of healthy aging in a Southern California community, researchers assessed the incidence of CHD events in 678 postmenopausal women aged 50 to 90 years over a follow-up of 20 years. Women were stratified into quintiles based on their testosterone levels, with those in the lowest quintile having testosterone levels of 80 pg/mL or less.
The study demonstrated that women with testosterone levels in the lowest quintile had a 2-fold increased risk of prevalent CHD, incident CHD (defined as a first-ever myocardial infarction or revascularization procedure), and CHD mortality. The findings were independent of the presence of CHD risk factors, diabetes, and metabolic syndrome.
"These results suggest that androgen deficiency may be a specific risk factor for atherosclerotic heart disease in postmenopausal women," said Dr. Laughlin, assistant adjunct professor of family and preventive medicine, University of California, San Diego, Calif. Whether the results apply only to women who are not current users of estrogen awaits further study.
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More